Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Abcam plc

ABCZFPNK
Healthcare
Biotechnology
$22.25
$0.15(0.68%)
U.S. Market opens in 8h 16m

Abcam plc Fundamental Analysis

Abcam plc (ABCZF) shows strong financial fundamentals with a PE ratio of 0.00, profit margin of 56.31%, and ROE of 28.53%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

ROE28.53%
PEG Ratio0.00
Current Ratio1.60

Areas of Concern

Operating Margin-18.47%
We analyze ABCZF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 78.7/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B
78.7/100

We analyze ABCZF's fundamental strength across five key dimensions:

Efficiency Score

Excellent

ABCZF demonstrates superior asset utilization.

ROA > 10%
30.19%

Valuation Score

Excellent

ABCZF trades at attractive valuation levels.

PE < 25
0.00
PEG Ratio < 2
0.00

Growth Score

Moderate

ABCZF shows steady but slowing expansion.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

ABCZF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
1.60

Profitability Score

Moderate

ABCZF maintains healthy but balanced margins.

ROE > 15%
28.53%
Net Margin ≥ 15%
56.31%
Positive Free Cash Flow
No

Key Financial Metrics

Is ABCZF Expensive or Cheap?

P/E Ratio

ABCZF trades at 0.00 times earnings. This suggests potential undervaluation.

0.00

PEG Ratio

When adjusting for growth, ABCZF's PEG of 0.00 indicates potential undervaluation.

0.00

Price to Book

The market values Abcam plc at 0.00 times its book value. This may indicate undervaluation.

0.00

EV/EBITDA

Enterprise value stands at 23.16 times EBITDA. This signals the market has high growth expectations.

23.16

How Well Does ABCZF Make Money?

Net Profit Margin

For every $100 in sales, Abcam plc keeps $56.31 as profit after all expenses.

56.31%

Operating Margin

Core operations generate -18.47 in profit for every $100 in revenue, before interest and taxes.

-18.47%

ROE

Management delivers $28.53 in profit for every $100 of shareholder equity.

28.53%

ROA

Abcam plc generates $30.19 in profit for every $100 in assets, demonstrating efficient asset deployment.

30.19%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

ABCZF converts -0.25% of its market value into free cash.

-0.25%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

0.00

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.00

vs 25 benchmark

P/S Ratio

Price to sales ratio

16.98

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.005

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.60

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.29

vs 25 benchmark

ROA

Return on assets percentage

0.30

vs 25 benchmark

ROCE

Return on capital employed

-0.12

vs 25 benchmark

How ABCZF Stacks Against Its Sector Peers

MetricABCZF ValueSector AveragePerformance
P/E Ratio0.0029.45 Better (Cheaper)
ROE28.53%779.00% Weak
Net Margin56.31%-24936.00% (disorted) Strong
Debt/Equity0.000.26 Strong (Low Leverage)
Current Ratio1.604.65 Neutral
ROA30.19%-19344.00% (disorted) Strong

ABCZF outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Abcam plc's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ